Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine versus liposomal amphotericin B for mucosal leishmaniasis
RBR-5r93wnPhase 3Not yet recruiting
- Sponsor
- Instituto René Rachou
- Start
- Mar 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of miltefosine and liposomal amphotericin b in mucocutaneous leishmaniasis (MCL) (3 arms), sponsored by Instituto René Rachou. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
miltefosineliposomal amphotericin b
03
Conditions
mucocutaneous leishmaniasis (MCL)
Beyond the preview
Go deeper on RBR-5r93wn.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5r93wn.